News
15h
TipRanks on MSNMerck Stock (MRK) Bulls Cheer $10Bn Verona Pharma GambleMerck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...
Verona brings with it Ohtuvayre, an inhaled treatment for chronic obstructive pulmonary disease, often known as smoker's lung ...
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
M erck said Wednesday it would pay $10 billion to buy the biotech Verona Pharma, which sells a new lung-disease drug that ...
Merck & Co – known as MSD outside of the US and Canada – has announced that it will be expanding its respiratory diseases ...
Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...
Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...
Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...
Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...
Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...
Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...
5d
Pharmaceutical Technology on MSNMerck agrees to acquire Verona Pharma for $10bnMerck has entered a definitive agreement to acquire biopharmaceutical company Verona Pharma in a deal valued at $10bn.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results